SGLT2 Inhibitors: What They Do

SGLT2 inhibitors began as diabetes medicines but have become some of the most talked-about drugs in medicine for a surprising reason: they turned out to protect the heart and kidneys, sometimes in people without diabetes at all. With unusual names ending in flozin, they are a good example of a treatment whose benefits proved wider than anyone first expected, and they are worth understanding plainly.

This is a companion piece for people curious about SGLT2 inhibitors. It is not medical advice. It is an honest overview of what they do, and it is no substitute for the guidance of the clinician who prescribes and monitors yours.

What they do

SGLT2 inhibitors lower blood sugar in an unusual way: rather than acting on insulin, they cause the kidneys to remove excess glucose from the body through the urine. This makes them useful in type 2 diabetes, described in our companion piece on living with type 2 diabetes, often alongside other treatments. Because they work through the kidneys and have effects on fluid and the heart, their influence reaches beyond blood sugar, which is where their wider story begins.

Why they protect the heart and kidneys

The reason these drugs became so significant is that large studies showed they reduce the risk of worsening kidney disease and of heart failure, benefits that hold even for some people who do not have diabetes. As a result, they are now used not only for diabetes but also to protect the kidneys in chronic kidney disease, described in our companion piece on living with chronic kidney disease, and to treat and prevent the heart strain our companion piece on living with heart failure describes. People are often surprised that a diabetes drug became a key heart and kidney medicine, a reminder of how interconnected these systems are.

The cautions that matter

As with any medicine, there are real cautions. Because they increase glucose in the urine, SGLT2 inhibitors can raise the risk of genital and urinary infections for some people, and attention to hydration and hygiene helps. There is an uncommon but important risk of a serious condition called diabetic ketoacidosis, which can occur even when blood sugar is not very high, so people are taught warning signs and when to stop the drug, such as during serious illness. They are not suitable for everyone, and doses and monitoring are individualised. People should follow their clinician's guidance closely. None of this is a prescription for you; it is the ground others navigate with professional supervision.

A wider benefit than expected

What makes SGLT2 inhibitors notable is how their value expanded from controlling blood sugar to protecting two vital organ systems, changing guidelines and helping many people. They are not a fit for everyone, and their cautions are real, but for the right person they can offer benefits well beyond their original purpose. As ever, whether one suits you is a conversation for your own clinician, who can weigh the benefits and risks for your situation.

If this is relevant to you, you can explore more in our Diabetes & Blood Sugar collection.

This article is a companion, not medical advice. It reflects what people commonly describe; everyone is different. SGLT2 inhibitors should be prescribed and monitored by a qualified clinician who knows your history.